PIK3CA and melanoma: Alpelisib, already FDA approved for HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer (45), is being tested in head and neck squamous cell carcinoma, melanoma, multiple myeloma, gastric cancer, pancreatic cancer, and ovarian cancer.